deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT03376672

Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

A Prospective Phase 2 Study to Assess the Minimal Residual Disease After Ixazomib Plus Lenalidomide Plus Dexamethasone (IRd) Treatment for Newly Diagnosed Transplant Eligible Myeloma Patients

Sponsor: Celgene

Conditions Multiple Myeloma
Interventions Dexamethasone Ixazomib Lenalidomide
Updated 14 times since 2018 Last updated: Mar 31, 2025 Started: May 31, 2018 Primary completion: Dec 31, 2027 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Myeloma, this trial is ongoing. The trial is conducted by Celgene and has accumulated 14 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Jan 2020 · 11 months · monthly snapshot~Jan 2020 – ~Aug 2020 · 7 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2022 · 13 months · monthly snapshot~Apr 2022 – ~Oct 2023 · 18 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 9 earlier versions

  1. Apr 2022 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jan 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  6. Feb 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  7. Aug 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE2

  9. Jan 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene
  • Nordic Myeloma Study Group
  • Raija Silvennoinen
  • Takeda
Data source: Helsinki University Central Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Borås, Sweden , Førde, Norway , Gothenburg, Sweden , Halmstad, Sweden , Helsinki, Finland , Jyväskylä, Finland , Kajaani, Finland , Kotka, Finland , Kuopio, Finland , Lahti, Finland and 16 more locations